IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Currently Amended): Use of A pharmaceutical composition for treating rosacea, comprising a rosacea treating effective amount of a compound that increases the binding of at least one natural ligand to a receptor chosen from the group comprising the IL-8RB receptor and the PAC-1 receptor, with the exception of proviso that the compound is not metronidazole, for the preparation of a pharmaceutical composition for treating rosacea.

Claim 2 (Currently Amended): [[Use]] <u>The composition</u> according to Claim 1, eharacterized in that the <u>wherein</u> said compound increases the binding of a natural ligand to the IL-8RB receptor and of a natural ligand to the PAC-1 receptor.

Claim 3 (Currently Amended): [[Use]] <u>The composition</u> according to Claim 1 [[or 2]], <u>eharacterized in that the wherein</u> said pharmaceutical composition is a dermatological composition for topical application.

Claim 4 (Currently Amended): [[Use]] The composition according to any one of Claims 1 to 3, characterized in that Claim 1, wherein the composition is for treating at least one stage of rosacea.

Claim 5 (Currently Amended): [[Use]] The composition according to any one of

Claims 1 to 4, characterized in that Claim 1, wherein the composition is for treating the first stage of rosacea.

Claim 6 (Currently Amended): [[Use]] The composition according to any one of Claims 1 to 5, characterized in that Claim 1, wherein the composition is for treating the second stage of rosacea.

b

Claim 7 (Currently Amended): [[Use]] <u>The composition</u> according to any one of <u>Claims 1 to 6</u>, characterized in that <u>Claim 1</u>, wherein the composition is for treating the third stage of rosacea.

Claim 8 (Currently Amended): [[Use]] The composition according to any one of Claims 1 to 7, characterized in that Claim 1, wherein the composition is for treating the fourth stage of rosacea.

Claim 9 (Currently Amended): [[Use]] The composition according to any one of Claims 1 to 8, characterized in that Claim 1, wherein the composition contains from about 0.0001% to 20% of [[the]] said modulator, preferably from 0.1% to 2% of the said modulator and more preferentially from about 0.75% to 1% by weight of the said modulator.

Claims 1 to 9, characterized in that the Claim 1, wherein said composition also contains further comprises another active agent chosen from the group of antibiotics, antibacterial agents, antiviral agents, antiparasitic agents, antifungal agents, anaesthetics, analgesics, antiallergic agents, retinoids, free-radical scavengers, anti-pruriginous agents, kerato-lytic agents, anti-seborrhoeic agents, antihistamines, sulfides, immunosuppressant products and anti-proliferative products.

Claims 1 to 10, characterized in that Claim 1, wherein the composition contains further comprises an additive chosen from the group of sequestrants, antioxidants, sunscreens, preserving agents, fillers, electrolytes, humectants, dyes, common mineral or organic acids or bases, fragrances, essential oils, cosmetic active agents, moisturizers, vitamins, essential fatty acids, sphingolipids, self-tanning compounds, calmatives and skin-protecting agents, propenetrating agents and gelling agents, or a mixture thereof.

ø

Claim 12 (New): The composition according to Claim 9, wherein the composition contains from 0.1% to 2% by weight of said modulator.

Claim 13 (New): The composition according to Claim 12, wherein the composition contains from about 0.75% to 1% by weight of said modulator.